

Table S3. The positive and negative predictive values of the combination of “postmenopausal status + CA125 \geq 35 U/ml” for concurrent EC in final histopathology of 447 preoperative-AEH patients ^a with available serum CA125 value.

	Total preoperative-AEH patients (<i>n</i>)	Final histopathology		Positive predictive value (%)	Negative predictive value (%)
		final-EC (<i>n</i>)	final-AEH (<i>n</i>)		
Postmenopausal status+ CA125 \geq 35 U/ml	6	5	1	83.3% (5/6)	-
Others ^b	441	125	316	-	71.7% (316/441)
Total (<i>n</i>)	447	130	317	-	-

Data shown were number or percentage.

^a In total of 447 patients who had serum CA125 value with available data.

^b These patients included the preoperative-AEH patients with “premenopausal status + CA125 < 35 U/ml” and “either postmenopausal status or CA125 \geq 35 U/ml”.

Notes: According to menopause status and serum of CA125 level, 447 preoperative-AEH patients were divided into three subgroups: “premenopausal status + CA125 < 35 U/ml” (no risk factor), “either postmenopausal status or CA125 \geq 35 U/ml” (either one risk factor) and “postmenopausal status + CA125 \geq 35 U/ml” (both risk factors).

Abbreviations: AEH: atypical endometrial hyperplasia; EC: endometrial cancer; final-AEH: atypical endometrial hyperplasia diagnosed by final histopathology; final-EC: endometrial cancer diagnosed by final histopathology; CA125, cancer antigen 125.